[HTML][HTML] Real-world outcomes of Intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema in Türkiye: MARMASIA study group report No …
U Yayla, MO Sevik, VL Karabaş, Ö Şahin… - Turkish Journal of …, 2023 - ncbi.nlm.nih.gov
Objectives: This study aimed to report the demographic and clinical characteristics of
diabetic macular edema (DME) patients treated with intravitreal injection (IVI) of anti …
diabetic macular edema (DME) patients treated with intravitreal injection (IVI) of anti …
[HTML][HTML] Rationale and design of VOYAGER: long-term outcomes of faricimab and port delivery system with ranibizumab for neovascular age-related macular …
R Guymer, C Bailey, V Chaikitmongkol… - Ophthalmology …, 2024 - Elsevier
Purpose To describe the rationale and design of the VOYAGER (NCT05476926) study,
which aims to investigate the safety and effectiveness of faricimab and the Port Delivery …
which aims to investigate the safety and effectiveness of faricimab and the Port Delivery …
A new approach for semi-parametric regression analysis of bivariate interval-censored outcomes from case-cohort studies
Y Lou, P Wang, J Sun - Communications in Statistics-Theory and …, 2024 - Taylor & Francis
Interval-censored failure time data frequently occur in many areas and a great deal of
literature on their analyses has been established. In this article, we discuss the situation …
literature on their analyses has been established. In this article, we discuss the situation …
Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
C Bührer, T Paling, R Gale, T Paulo… - PharmacoEconomics-Open, 2024 - Springer
Aim The aim of this work was to evaluate the cost-effectiveness of faricimab against relevant
therapeutic alternatives used in clinical practice for the treatment of diabetic macular …
therapeutic alternatives used in clinical practice for the treatment of diabetic macular …
Visual and Anatomical Outcomes of a Single Intravitreal Dexamethasone in Diabetic Macular Edema: An 8 Year Real-World Study
L Faes, AV Mishra, V Lipkova, K Balaskas… - Journal of Clinical …, 2023 - mdpi.com
Importance: Diabetic macular edema (DME) is a major cause of vision loss in patients with
diabetes mellitus. Intravitreal dexamethasone is a treatment option for patients unsuitable for …
diabetes mellitus. Intravitreal dexamethasone is a treatment option for patients unsuitable for …
Diabetic macular edema: genetics and treatment response
RL Gurung - 2024 - figshare.utas.edu.au
Diabetic macular edema (DME), the most common cause of vision loss in people with
diabetes, is a complex disease affecting the central part of the retina. The exact …
diabetes, is a complex disease affecting the central part of the retina. The exact …
Das diabetische Makulaödem-Patientenkollektiv und Behandlungsrealität in einem Universitätsklinikum
AM Eder - 2024 - archiv.ub.uni-marburg.de
Das diabetische Makulaödem ist mit einem relevanten Visusverlust assoziiert. Den aktuellen
Goldstandard zur Behandlung dieser Erkrankung stellen intravitreale Injektionen mit einem …
Goldstandard zur Behandlung dieser Erkrankung stellen intravitreale Injektionen mit einem …
[HTML][HTML] Türkiye'de Diyabetik Maküla Ödeminde İntravitreal Anti-Vasküler Endotelyal Büyüme Faktör Tedavisinin Gerçek Yaşam Sonuçları: MARMASIA Çalışma Grubu …
U Yayla, MO Sevik, VL Karabaş, Ö Şahin… - Turk J …, 2023 - oftalmoloji.org
Amaç: Bu çalışmanın amacı Türkiye'de rutin pratikte anti-vasküler endoteliyal büyüme
faktörü (anti-VEBF) intravitreal enjeksiyonu (İVE) uygulanan diyabetik maküla ödemi (DMÖ) …
faktörü (anti-VEBF) intravitreal enjeksiyonu (İVE) uygulanan diyabetik maküla ödemi (DMÖ) …
[引用][C] Das diabetische Makulaödem-Patientenkollektiv und Behandlungsrealität in einem Universitätsklinikum
W Sekundo - 2024